Literature DB >> 35986758

Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.

Rirong Qu1, Fan Ye1, Shaojie Hu1, Boyu Wang1, Shenghui Qin2, Jing Xiong2, Xiangning Fu1, Lequn Li1, Yixin Cai3.   

Abstract

INTRODUCTION: Ground glass opacity featured lung adenocarcinomas (GGO-LUAD) display more indolent biological behavior than solid nodule featured lung adenocarcinomas (SN-LUAD) and have an excellent prognosis. However, the cellular immune characteristics of GGO-LUAD remain poorly understood.
METHODS: Immunohistochemistry technique was performed to stain related immune markers (CD8, CD103, CD20, CD138, CD4, FOXP3, CD68, CD163, PD-1 and PD-L1) and TGF-β from 15 patients with pure GGO-LUAD and 15 patients with SN-LUAD tissue sections (Paired cohort), and then, the related markers with significant differences were verified on 10 patients (Verified cohort) with both pure GGO-LUAD and SN-LUAD. For localization analysis of CD68 + tumor-associated macrophages (TAMs) and FOXP3 + Terg cells in tumor areas, pure GGO-LUAD and SN-LUAD were also stained for simultaneous detection of pan-CK, CD68 and FOXP3 by multiplex immunofluorescence.
RESULTS: In the Paired cohort, compared with SN-LUAD, only the infiltration of TAMs and Treg cells was significantly lower in GGO-LUAD. The infiltration of the remaining immune cells including CD8 + T cells, CD4 + T cells, CD103 + T cells, CD20 + B cells and CD138 + Plasma cells in GGO-LUAD, although relatively low, was not significantly different. Meanwhile, the expression of TGF-β was significantly higher in SN-LUAD. And the above results have also been confirmed in the Verified cohort. Moreover, there was no significantly difference in PD-L1 expression in GGO-LUAD compared to SN-LUAD both in the Paired cohort and Verified cohort.
CONCLUSIONS: GGO-LUAD demonstrates an overall less active immune landscape as compared with SN-LUAD. TAMs and TGF-β may play an important role in the progression of GGO-LUAD. More importantly, PD-L1 expression in GGO-LUAD is comparable to that in SN-LUAD, indicating that there may be other reasons for the insensitivity of GGO-LUAD to immunotherapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Ground glass opacity; Immune cell infiltration; Lung adenocarcinomas; Tumor immune microenvironment

Year:  2022        PMID: 35986758     DOI: 10.1007/s00432-022-04289-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  42 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Immunotherapy in Non-Small Cell Lung Cancer. Which Patients and at Which Stage?

Authors:  James P Allinson; James Brown; Kate Gibb; Neal Navani
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

3.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Authors:  Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer
Journal:  Lung Cancer       Date:  2015-05-18       Impact factor: 5.705

Review 4.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

Review 5.  The polarization of immune cells in the tumour environment by TGFbeta.

Authors:  Richard A Flavell; Shomyseh Sanjabi; Stephen H Wrzesinski; Paula Licona-Limón
Journal:  Nat Rev Immunol       Date:  2010-07-09       Impact factor: 53.106

6.  Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.

Authors:  Hitoshi Dejima; Xin Hu; Runzhe Chen; Jiexin Zhang; Junya Fujimoto; Edwin R Parra; Cara Haymaker; Shawna M Hubert; Dzifa Duose; Luisa M Solis; Dan Su; Junya Fukuoka; Kazuhiro Tabata; Hoa H N Pham; Nicholas Mcgranahan; Baili Zhang; Jie Ye; Lisha Ying; Latasha Little; Curtis Gumbs; Chi-Wan Chow; Marcos Roberto Estecio; Myrna C B Godoy; Mara B Antonoff; Boris Sepesi; Harvey I Pass; Carmen Behrens; Jianhua Zhang; Ara A Vaporciyan; John V Heymach; Paul Scheet; J Jack Lee; Jia Wu; P Andrew Futreal; Alexandre Reuben; Humam Kadara; Ignacio I Wistuba; Jianjun Zhang
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

7.  Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity.

Authors:  Kezhong Chen; Jing Bai; Alexandre Reuben; Heng Zhao; Guannan Kang; Chunliu Zhang; Qingyi Qi; Yaping Xu; Shawna Hubert; Lianpeng Chang; Yanfang Guan; Lin Feng; Kai Zhang; Kaitai Zhang; Xin Yi; Xuefeng Xia; Shujun Cheng; Fan Yang; Jianjun Zhang; Jun Wang
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

8.  Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer.

Authors:  Jian Chen; Yun Tan; Fenghuan Sun; Likun Hou; Chi Zhang; Tao Ge; Huansha Yu; Chunxiao Wu; Yuming Zhu; Liang Duan; Liang Wu; Nan Song; Liping Zhang; Wei Zhang; Di Wang; Chang Chen; Chunyan Wu; Gening Jiang; Peng Zhang
Journal:  Genome Biol       Date:  2020-06-24       Impact factor: 13.583

9.  Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.

Authors:  Nasser K Altorki; Alain C Borczuk; Sebron Harrison; Lauren K Groner; Bhavneet Bhinder; Vivek Mittal; Olivier Elemento; Timothy E McGraw
Journal:  Cell Rep       Date:  2022-04-05       Impact factor: 9.995

10.  Genomic and immune profiling of pre-invasive lung adenocarcinoma.

Authors:  Haiquan Chen; Jian Carrot-Zhang; Yue Zhao; Haichuan Hu; Samuel S Freeman; Su Yu; Gavin Ha; Alison M Taylor; Ashton C Berger; Lindsay Westlake; Yuanting Zheng; Jiyang Zhang; Aruna Ramachandran; Qiang Zheng; Yunjian Pan; Difan Zheng; Shanbo Zheng; Chao Cheng; Muyu Kuang; Xiaoyan Zhou; Yang Zhang; Hang Li; Ting Ye; Yuan Ma; Zhendong Gao; Xiaoting Tao; Han Han; Jun Shang; Ying Yu; Ding Bao; Yechao Huang; Xiangnan Li; Yawei Zhang; Jiaqing Xiang; Yihua Sun; Yuan Li; Andrew D Cherniack; Joshua D Campbell; Leming Shi; Matthew Meyerson
Journal:  Nat Commun       Date:  2019-11-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.